These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 29055736)

  • 1. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 3. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Prediction Models for Identifying Malignancy in Pulmonary Nodules Detected via Low-Dose Computed Tomography.
    González Maldonado S; Delorme S; Hüsing A; Motsch E; Kauczor HU; Heussel CP; Kaaks R
    JAMA Netw Open; 2020 Feb; 3(2):e1921221. PubMed ID: 32058555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.
    Patz EF; Greco E; Gatsonis C; Pinsky P; Kramer BS; Aberle DR
    Lancet Oncol; 2016 May; 17(5):590-9. PubMed ID: 27009070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.
    Chang GC; Chiu CH; Yu CJ; Chang YC; Chang YH; Hsu KH; Wu YC; Chen CY; Hsu HH; Wu MT; Yang CT; Chong IW; Lin YC; Hsia TC; Lin MC; Su WC; Lin CB; Lee KY; Wei YF; Lan GY; Chan WP; Wang KL; Wu MH; Tsai HH; Chian CF; Lai RS; Shih JY; Wang CL; Hsu JS; Chen KC; Chen CK; Hsia JY; Peng CK; Tang EK; Hsu CL; Chou TY; Shen WC; Tsai YH; Tsai CM; Chen YM; Lee YC; Chen HY; Yu SL; Chen CJ; Wan YL; Hsiung CA; Yang PC;
    Lancet Respir Med; 2024 Feb; 12(2):141-152. PubMed ID: 38042167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
    Walter JE; Heuvelmans MA; de Jong PA; Vliegenthart R; van Ooijen PMA; Peters RB; Ten Haaf K; Yousaf-Khan U; van der Aalst CM; de Bock GH; Mali W; Groen HJM; de Koning HJ; Oudkerk M
    Lancet Oncol; 2016 Jul; 17(7):907-916. PubMed ID: 27283862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving selection criteria for lung cancer screening. The potential role of emphysema.
    Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
    Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience.
    Menezes RJ; Roberts HC; Paul NS; McGregor M; Chung TB; Patsios D; Weisbrod G; Herman S; Pereira A; McGregor A; Dong Z; Sitartchouk I; Boerner S; Tsao MS; Keshavjee S; Shepherd FA
    Lung Cancer; 2010 Feb; 67(2):177-83. PubMed ID: 19427055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population.
    Goffin JR; Pond GR; Puksa S; Tremblay A; Johnston M; Goss G; Nicholas G; Martel S; Bhatia R; Liu G; Schmidt H; Atkar-Khattra S; McWilliams A; Tsao MS; Tammemagi MC; Lam S
    BMC Pulm Med; 2020 Nov; 20(1):300. PubMed ID: 33198781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screen-detected subsolid pulmonary nodules: long-term follow-up and application of the PanCan lung cancer risk prediction model.
    Zhao H; Marshall HM; Yang IA; Bowman RV; Ayres J; Crossin J; Lau M; Slaughter RE; Redmond S; Passmore L; McCaul E; Courtney D; Leong SC; Windsor M; Zimmerman PV; Fong KM
    Br J Radiol; 2016; 89(1060):20160016. PubMed ID: 26882046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study.
    Marquette CH; Boutros J; Benzaquen J; Ferreira M; Pastre J; Pison C; Padovani B; Bettayeb F; Fallet V; Guibert N; Basille D; Ilie M; Hofman V; Hofman P;
    Lancet Respir Med; 2020 Jul; 8(7):709-716. PubMed ID: 32649919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.
    Sundaram V; Gould MK; Nair VS
    Chest; 2021 Mar; 159(3):1273-1282. PubMed ID: 33393476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis.
    Rampinelli C; De Marco P; Origgi D; Maisonneuve P; Casiraghi M; Veronesi G; Spaggiari L; Bellomi M
    BMJ; 2017 Feb; 356():j347. PubMed ID: 28179230
    [No Abstract]   [Full Text] [Related]  

  • 20. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.
    Cressman S; Peacock SJ; Tammemägi MC; Evans WK; Leighl NB; Goffin JR; Tremblay A; Liu G; Manos D; MacEachern P; Bhatia R; Puksa S; Nicholas G; McWilliams A; Mayo JR; Yee J; English JC; Pataky R; McPherson E; Atkar-Khattra S; Johnston MR; Schmidt H; Shepherd FA; Soghrati K; Amjadi K; Burrowes P; Couture C; Sekhon HS; Yasufuku K; Goss G; Ionescu DN; Hwang DM; Martel S; Sin DD; Tan WC; Urbanski S; Xu Z; Tsao MS; Lam S
    J Thorac Oncol; 2017 Aug; 12(8):1210-1222. PubMed ID: 28499861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.